Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives $4.93 Average PT from Brokerages

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has earned a consensus recommendation of “Hold” from the seven research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $4.93.

A number of brokerages have issued reports on SGMO. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $2.00 price objective on shares of Sangamo Therapeutics in a report on Thursday, March 14th. HC Wainwright restated a “buy” rating and set a $5.00 target price (up previously from $3.00) on shares of Sangamo Therapeutics in a research report on Tuesday, March 19th. Finally, StockNews.com began coverage on shares of Sangamo Therapeutics in a report on Tuesday, February 13th. They issued a “sell” rating on the stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Wasatch Advisors LP increased its stake in Sangamo Therapeutics by 62.4% during the first quarter. Wasatch Advisors LP now owns 20,132,324 shares of the biopharmaceutical company’s stock worth $13,493,000 after acquiring an additional 7,734,400 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Sangamo Therapeutics by 14.4% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,033,322 shares of the biopharmaceutical company’s stock valued at $561,000 after purchasing an additional 129,811 shares during the last quarter. Acadian Asset Management LLC raised its holdings in Sangamo Therapeutics by 3.7% during the 3rd quarter. Acadian Asset Management LLC now owns 2,927,769 shares of the biopharmaceutical company’s stock valued at $1,753,000 after buying an additional 105,789 shares during the period. SG Americas Securities LLC lifted its position in Sangamo Therapeutics by 103.9% in the fourth quarter. SG Americas Securities LLC now owns 180,544 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 92,002 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Sangamo Therapeutics by 10.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 676,189 shares of the biopharmaceutical company’s stock worth $406,000 after buying an additional 62,465 shares during the period. Institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Stock Performance

Shares of SGMO stock opened at $0.50 on Tuesday. The stock has a fifty day simple moving average of $0.80 and a two-hundred day simple moving average of $0.59. The firm has a market capitalization of $104.37 million, a PE ratio of -0.34 and a beta of 1.39. Sangamo Therapeutics has a 52-week low of $0.29 and a 52-week high of $1.78.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.09). The business had revenue of $2.04 million for the quarter, compared to analysts’ expectations of $8.96 million. Sangamo Therapeutics had a negative return on equity of 82.17% and a negative net margin of 146.30%. On average, sell-side analysts forecast that Sangamo Therapeutics will post -0.54 EPS for the current fiscal year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.